MetaVia Inc. 8-K

What Happened

• MetaVia Inc. (MTVA) announced on May 18, 2026 (via an 8‑K Regulation FD disclosure and attached press release) that three late‑breaking abstracts highlighting its cardiometabolic programs were accepted for poster presentations at the American Diabetes Association (ADA) 2026 Scientific Sessions.
• The ADA meeting runs June 5–8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Two programs named in the filing are DA‑1726, a novel dual oxyntomodulin (OXM) analog targeting GLP‑1 and glucagon receptors, and vanoglipel (DA‑1241), a GPR119 agonist.

Key Details

• Filing date: May 18, 2026; press release attached as Exhibit 99.1 to the Form 8‑K.
• Accepted: three late‑breaking abstracts for poster presentations at ADA 2026.
• Programs highlighted: DA‑1726 (dual OXM analog targeting GLP1R and GCGR) and vanoglipel (DA‑1241, a GPR119 agonist).
• ADA 2026 dates/venue: June 5–8, 2026, Ernest N. Morial Convention Center, New Orleans.

Why It Matters

• Acceptance of late‑breaking abstracts at a major scientific meeting gives MetaVia a public forum to present data and discuss its cardiometabolic pipeline with diabetes researchers, clinicians, and potential partners. The disclosure is procedural information for investors about upcoming scientific visibility for DA‑1726 and vanoglipel and is documented in the company’s 8‑K.